Try our Advanced Search for more refined results

MYLAN PHARMACEUTICALS INC. v. WARNER CHILCOTT PUBLIC LIMITED COMPANY et al

  1. May 15, 2015

    Mylan To Appeal Dismissal Of Doryx Product-Hopping Suit

    Mylan Pharmaceuticals Inc. told a Pennsylvania federal judge Thursday that it would urge the Third Circuit to overturn his ruling that tossed the generic-drug maker's allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula.

  2. April 16, 2015

    Warner Chilcott Nabs Win In Generic Doryx Delay Row

    A Pennsylvania federal judge on Thursday tossed Mylan Pharmaceuticals Inc.'s allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula, ruling any damage Mylan suffered was due to its own business strategy.

  3. July 14, 2014

    Warner Chilcott To Pay $8M Over Generic Doryx Delay

    Warner Chilcott PLC promised Friday to pay $8 million to settle antitrust claims made in Pennsylvania federal court by indirect purchasers of the acne medication Doryx, who said the company prevented a generic version of the drug from coming to market.

  4. May 02, 2014

    Warner Chilcott Rips Mylan Bid For Quick Win In Doryx Case

    Warner Chilcott PLC has taken a shot at Mylan Pharmaceuticals Inc.'s bid for summary judgment in its lawsuit alleging Warner had tried to block generic competition to the acne medication Doryx by tweaking the pill, arguing that the company's "product hopping" theory did not hold up.

  5. November 20, 2013

    Doryx Indirect Purchasers Denied Cert. In Warner Antitrust Suit

    A Pennsylvania federal judge on Wednesday denied a bid to certify a proposed class of indirect purchasers who are accusing Warner Chilcott PLC of making small tweaks to its severe acne medication Doryx as a tactic to stave off generics.

  6. June 12, 2013

    Warner Chilcott Can't Duck Consolidated Doryx Antitrust Row

    A Pennsylvania federal judge Wednesday denied Warner Chilcott PLC's motions to dismiss several complaints in a consolidated antitrust dispute alleging it had tried to block generic competition to the acne medication Doryx by tweaking the pill, saying the motions were premature.

  7. May 29, 2013

    Doryx Antitrust Class Cert. Bids Fall Short, Warner Says

    An antitrust lawsuit accusing Warner Chilcott PLC of attempting to stymie a generic version of the acne medication Doryx "falls woefully short" of the requirements for class action certification, the company told a Pennsylvania federal court Wednesday.

  8. March 08, 2013

    Warner 'Confused' About Doryx Contracts, Retailers Say

    Walgreen Co., Safeway Inc. and other retailers struck back Thursday against Warner Chilcott PLC's attempt to upend their antitrust suit over the drugmaker's efforts to stymie a generic form of Doryx, saying the manufacturer is "confused" about contractual terms it's citing as roadblocks to the litigation.

  9. February 28, 2013

    Warner Chilcott Says Contracts Bar Retailers' Doryx Suit

    Warner Chilcott PLC said Wednesday that contracts it has with Doryx wholesalers prevent Walgreen Co., Safeway Inc. and two other retailers from suing the drugmaker in Pennsylvania for allegedly preventing competitors from developing a lower-cost generic version of the skin infection treatment.

  10. November 27, 2012

    Tweaking Brand-Name Drugs Can Hurt Competition, FTC Says

    The Federal Trade Commission has told the Pennsylvania federal court considering a consolidated antitrust suit against Warner Chilcott PLC that minor, nontherapeutic changes to a branded drug can represent exclusionary conduct and harm competition from generics makers, the agency said Tuesday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!